Aposave and Laboratoires CTRS enter strategic partnership
The strategic partnership will drive awareness and treatment of Bile Acid Synthesis Disorders in the Benelux region.
PRESS RELEASE
Aposave Ltd and Laboratoires CTRS are proud to announce the signing of an exclusive contract to drive awareness and diagnosis of primary Bile Acid Synthesis Disorders (BASD) across the Benelux countries – Belgium, the Netherlands and Luxembourg.
The agreement provides exclusive distribution rights for Orphacol® (cholic acid) to the Benelux countries. In addition, Aposave has been contracted to support and drive the identification of patients with primary BASD through a program of:
- Market Research and Access Support
- Medical Awareness and Clinician Engagement
- Diagnostic Support
Simon Estcourt, Aposave Managing Director explains: “I am extremely proud of our Commercial Partnerships Team. They continue to do a fantastic job for our partners Laboratoires CTRS in the UK, and we are now adding Benelux to our joint projects. Aposave’s ambition, as part of the Abacus Medicine Group, is to provide better access to medicines to all patient groups and this project supporting a rare disease like BASD is a perfect fit.”
“We are pleased to extend our partnership with the Aposave team who already provide active support in the UK. This new adventure in Benelux represents an important step for patients suffering from often life-threatening bile acid synthesis disorders in these countries and allows Laboratoires CTRS to expand its reach for the benefit of those patients,” says Antoine Ferry, CEO of Laboratoires CTRS.
